Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143448 | 0.93 | ALDH1A1 (0.59) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL2629477 | 0.88 | CYP2D6 (0.57) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL31015335 | 0.83 | CHRM3 (0.53) | TSHRALDH1A1CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL13943667 | 0.78 | SIGMAR1 (0.64) | TSHRMEN1KMT2AALDH1A1HRH3 | |
| SCHEMBL1732446 | 0.77 | CYP2D6 (0.65) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL31014864 | 0.77 | ALDH1A1 (0.55) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL15236204 | 0.77 | ALDH1A1 (0.77) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL24798656 | 0.76 | CYP2D6 (0.68) | TSHRMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL2336883 | 0.76 | KDM4E (0.65) | TSHRMEN1KMT2AALDH1A1HRH3 | |
| SCHEMBL24798927 | 0.76 | CYP2D6 (0.68) | TSHRMEN1KMT2AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007140383-A2 | SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140383-A2 | SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | TSHR 198/4885MEN1 1522/4885KMT2A 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.